NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Parkinson's disease
Date of first enrollment	28/03/2007
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : AD-810N (zonisamide) INN of investigational material : Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administration for Investigational material : oral

Outcome(s)

Primary Outcome	Unified Parkinson's Disease Rating Scale (UPDRS)
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	<= 74age old
Gender	Both
Include criteria	[Major inclusion criteria] - Patients with reduced response to L-DOPA - Age: >=20 and <75 (at the time of informed consent) [Major exclusion criteria] - Patients with Parkinson's syndrome other than Parkinson's disease - Patients with epilepsy - Patients with a history of treatment with zonisamide, or who have ever enrolled in other clinical trials related to AD-810N - Patients with a history of neuroleptic malignant syndrome
Exclude criteria